RxDoctor Payments Data

Stephen Ryan, MD

Critical Care Medicine · Tacoma, WANPI 1427107978

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by GSK at 57.0% of the total. That places this record below the midpoint for critical care medicine clinicians in WA, where the typical reported total is $138.

$127in general payments, 2019–2025

Across 5 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$72
  • Amgen$29
  • Sanofi$26
$276,094in research payments, 2019–2025

Across 78 payments — averaging $3539.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$74K
  • AstraZeneca$62K
  • Sanofi US Services Inc.$49K
  • GSK$38K
  • Boehringer Ingelheim$21K
  • Insmed, Inc.$12K
  • plus $19K from 6 others

What the payments were for

  • Food & beverage$127100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$72
Amgen1$29
Sanofi1$26

How this compares

$127 in reported general payments places this provider in the 45th percentile of 115 critical care medicine providers in Washington.

See all critical care medicine providers in Washington

Medicare billing

Part B allowed, 2024
$104,877
Medicare patients
419
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter164$154,791
ZemairaAlpha-1-Proteinase Inhibitor13$110,781
Breo ElliptaFluticasone/Vilanterol76$45,288
XolairOmalizumab12$41,766
Advair HfaFluticasone Propion/Salmeterol36$25,640
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$24,721
Spiriva HandihalerTiotropium Bromide24$24,022
Spiriva RespimatTiotropium Bromide12$18,768
SymbicortBudesonide/Formoterol Fumarate43$18,055
Incruse ElliptaUmeclidinium Bromide24$17,333
Arnuity ElliptaFluticasone Furoate42$12,663
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$11,107
Albuterol Sulfate HfaAlbuterol Sulfate302$10,340
Fluticasone-SalmeterolFluticasone Propion/Salmeterol49$9,811
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$8,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta$72$241,184318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 115 critical care medicine providers in Washington.

Other critical care medicine in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →